HB 243 (see similar bill HB 710) – LouisianaStatus: Inactive / Dead
Year Introduced: 2018
PROHIBITS A MANUFACTURER OR WHOLESALE DISTRIBUTOR FROM ENGAGING IN PRICE GOUGING IN THE SALE OF AN ESSENTIAL OFF-PATENT OR GENERIC DRUG. Authorizes the secretary of the La. Dept. of Health to notify the attorney general of any increase in the price of an essential off-patent or generic drug if the price increase, by itself or in combination with other price increases, would result in an increase of 50% or more in the wholesale acquisition cost of the drug or the price paid by the medical assistance program for the drug within the preceding one-year period and a 30-day supply of the maximum recommended dosage of the drug for any indication or a full course of treatment with the drug, according to the label for the drug approved under the federal Food, Drug, and Cosmetic Act, would cost more than $80 at the drug’s wholesale acquisition cost.
Return to Database Search
© 2018- The SLIHCQ Database. Initial funding for this project was provided by the Robert Wood Johnson Foundation. The views expressed here do not necessarily reflect the views of the Foundation.